Venetoclax Combined With CACAG Regimen Versus "3+7" Regimen in the Treatment of Acute Monocytic Leukemia

Inclusion Criteria: * Voluntary participation with written informed consent signed by the participant or a legal guardian; willingness to comply with all study procedures. * Age 14 to 60 years at screening, no gender restriction. * Diagnosis of acute monocytic leukemia according to the 2016 WHO classification, excluding acute promyelocytic leukemia. * No history of severe allergic reactions. * Liver function: ALT and AST ≤ 2.5 × upper limit of normal (ULN); total bilirubin ≤ 2 × ULN. * Renal function: serum creatinine ≤ 1.5 × ULN * No uncontrolled infection or severe psychiatric disorder. * ECOG performance status 0-3; life expectancy ≥ 4 months. Exclusion Criteria: * Known hypersensitivity or contraindication to any study drug. * Pregnancy or lactation. * Active infection. * Long-term smoking or alcohol abuse that may interfere with study outcome evaluation. * Psychiatric illness or other condition that prevents informed consent or compliance with study procedures. * Major organ surgery within 6 weeks prior to enrollment. * Abnormal liver function: total bilirubin \> 2× ULN, ALT/AST \> 2.5 × ULN; abnormal renal function: serum creatinine \> 1.5 × ULN. * Any condition deemed unsuitable for the study by the investigator (e.g., poor compliance, substance abuse).